関連する実験動画

Updated: Sep 9, 2025

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

ゼルウェガースペクトル症候群の希少合併症としての重症肝肺症候群の治療に成功

Riya Mary Tharakan¹, Sanjay Rajwal², Bernd C Schwahn^1,3

¹Manchester Centre for Genomic Medicine, St Mary's Hospital Manchester University NHS Foundation Trust, Health Innovation Manchester Manchester UK.

|September 2, 2025

まとめ

ヘパト肺症候群 (HPS) は,ゼルウェガースペクトル障害の希少な合併症で,11歳の少女の肝臓移植で治療に成功しました. この介入により彼女の酸素飽和度が正常化し肝臓移植が小児性ペロキシソーマ生殖障害の治療に有効であることを示しました

科学分野:

小児胃腸内科
ヘパトロジー
遺伝学
肺科

背景:

ゼルウェガースペクトル障害 (ZSD) は,希少な遺伝性ペロキシソーム生物発生障害のグループである.
肝臓肺症候群 (HPS) は肝臓疾患の希少な合併症であり,特に小児の患者で発生する.
ZSDの合併症の早期診断と管理は,患者のアウトカムにとって極めて重要です.

研究の目的:

ZSDの小児患者のHPSを報告する
この文脈で肝臓移植によるHPS治療の成功を強調する.
小児の肝疾患におけるHPSの認識の重要性を強調する.

主な方法:

ZSDの11歳の少女の症例報告
青色腫の診断にはエコーカルジオグラム,CT胸部,肝臓の超音波検査,超音波泡検査,そして perfusion scintigraphy が含まれる.
肝臓移植 (OLT) による治療

主要な成果:

患者はZSDに二次的なHPSと診断されました
オーソトピック肝移植 (OLT) は酸素飽和度の正常化をもたらした.
患者は11歳で酸素補給なしで臨床的に安定していた.

結論:

HPSはZSDの希少だが重大な合併症であり,OLTで成功裏に治療できます.
肝臓移植は,ペロキシソーマの生体形成障害を有する小児患者のHPSの有効な治療法です.
複合的な小児症例の結果を最適化するために多学科的な管理が不可欠です

キーワード:

ゼルヴェーガースペクトル障害肝肺症候群肝臓移植ペロキシソーマル生体形成障害

さらに関連する動画

Hepatocyte-specific Ablation in Zebrafish to Study Biliary-driven Liver Regeneration

Hepatocyte-specific Ablation in Zebrafish to Study Biliary-driven Liver Regeneration

Published on: May 20, 2015

Partial Hepatectomy in Adult Zebrafish

Partial Hepatectomy in Adult Zebrafish

Published on: April 4, 2021

関連する概念動画

Psychosis: Goals of Pharmacotherapy

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...

Acute Respiratory Failure-V

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...

Cystic Fibrosis: Management

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...

Chronic Obstructive Pulmonary Disease-V: Management

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation

Pneumonia IV: Management

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include: